Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Let’s hope so Chelsea. Would be interested to see how ADL has performed - there were some heavy performance related payments due late last year linked to EBIDTA for that division which look like have been missed. Also keen to see cash flow taking into account ongoing investments - and year end cash at hand. 2023 should be good here. SB
In 2020 it arrived as late as 29th, so yes, this week now hopefully. The last Results were solid (imo) and I’m really hoping the TU builds on that.
Really expected an update this week - looks like next week instead. Similarly might have expected a bounce into the update…..so todays movement a bit disappointing. Will be interesting to see how H2 fared v H1 - it will be down - key issue is by how much. SB
Ygen look rife for a takeover with Ekfs management this could be a good fit.
EKF have issued Trading Updates in January for a number of years and so reasonable to expect another this month.
Hopefully will build on most recent results.
Must be a great addition to vets in the horse racing industry?
Yes, more inked evidence of execution of well communicated, non-covid product expansion strategy.
Looking good here for 2023 IMO.
Nice RNS to help sp :-).
Maybe he’s bringing some good news…………..
Up 11% as I write on no news I can discern.... other than a rotund, jolly man dressed in red was sighted nearby. Ho, Ho, Ho!
Maybe Liontrust will have a look here … for diagnostic future …. https://www.adordx.com/about/technology/
We had an RNS yesterday which announced that Liontrust (Asset managers) had taken10% of EKF. I did some digging, as I thought a large transaction like that might have been more noticeable. I think they were on 9.79% previously. Although the RNS says previous position was 'blank'.
We can see some big trades coming through now, and even post the RNS, another trade dated for today. The ask is now a little above 45p, which has been quite a resistance. I think that is quite an accolade for EKF, when you listen to all these fund manager interviews on Vox Markets, a lot of these guys are talking about keeping dry powder, and how much is on offer from so many competing equities. Very happy that Liontrust are buying more here. I hold both. EKF my second largest position.
Yes, those were shares in Verici Dx plc. I had to call Best invest for another reason, and checked.
If you change SIPP providers, there is a redirect active for 6 months, so these should port across to II in due course.
I shall add VRCI to my watch list and begin my research on the company.
Has any one received those shares mentioned as a dividend? Verici Dx plc.
I have some unknown units in my account, that are probably those. My *online platform doesnt have every aim share, so for me the units say unknown, hence why I am asking. Can any one tell me what date they arrived also please.
*In the process of moving from Best invest to II due to issues like this. So all my shares have moved, except these unknown units. Probably not worth losing much sleep over as it wouldn't even buy a Mcdonnalds, but you never know, could be the next big thing.
Clarifying EKF's USD exposure, from slide 5 of their interim results presentation: the US makes up just over 45% of sales revenues, with Germany close to 40%, UK roughly 10% and Russia under 5%. The full presentation is on the company website, well worth the read.
Thanks SB, yes that's a good point about USD revenues, given the ongoing weakness in GBP this could add a few more % points to the bottom line in H2, unreal weakness in GBP, woeful.
Hawker - £35m H2 would be outstanding imo - let’s wait and see - it will come just think we might have to wait until 2023 to see that level of revenue. Agree with everything else - given we generated £45m revenue in 2019 and £12m EBITDA pre covid impact - our core business has been growing in low double digits for three years and looks set to increase into next two years. We will continue to see the benefit of a substantial portion of our revenue in $ v £. Would like to see some II or director purchases at this level to underpin and move away from 40p. As you say - would not be surprised if someone was not taking an interest in developments. ATB SB
Thanks SB. I'm optimistic on H2 revenues as we're beginning to see the revenue flows from the investment in Life Sciences/Enzyme business flow through and gain momentum, alongside wider growth across the business. I wouldn't be surprised to see H2 revs closer to £35m, in which case the mark-down on the back of FY results back in March should be unwound and the shares should frankly be at least around 50p in today's money. EKF has no debt, £19m of cash (after all the recent investment, ADL, Fermentation, etc), 3% dividend, FCF Yield of >5% and is in the process of returning to growth after managing the wind-down of the covid related business; not to mention they're doing a great job managing the current spike in inflation. I see this as a must have business and if the market doesn't afford it the appropriate multiples I'm sure the PE houses will. What's not to like?
Possibly not the most exciting set of results - and as usual greeted with selling - but all in all (share price aside) plenty to look forward to. I anticipate H2 will fall short of H1 in revenue and EDITDA as there was a continued benefit from covid in Q1 and the inventory sales - so could be looking at c.£30m. Life sciences looks like a real opportunity to establish a leading enzymes business in a growing market . Bit of negativity around cash locked up in Russia (plus the general exposure), some restructuring post covid in the manufacturing business, and the jury is still out on the ADL purchase imo - but I guess we paid little after the buy back - does not appear that the earn outs will be achieved on current performance. Good cash flow - and plenty of cash to invest in organic growth. Management are clearly focused on driving value - but this is not likely to materialise until 2023/2024. Looks good value at this price - 3% dividend in Dec on current share price. SB
Settle for a few days after big rollover then move up ? &hope so as i thought 60's after buy back... GL
that 1.4 mill rollover trade....filled.
... still 10% up on the day.
Reason elusive...
Thanks rivaldo. Never quite sure on what basis these p/e forward prices are based. Same goes for the ‘in line with management expectations’ and ‘current guidance’ type RNS announcements. As PI’s we mostly live in a world of financial shadows trying to second guess what these references really mean - don’t get me wrong I can do the math - but there’s a lot of inconsistency across the board. ATB. SB
Techinvest have published their new issue, so it should be OK to copy their Buy update on EKF from the July issue:
"EKF Diagnostics
EKF has announced the intention to distribute shares in its investment, Verici Dx, to the company’s shareholders who will receive one investment share for every 50 ordinary shares held in EKF. In order to maintain an orderly market in Verici’s shares following the distribution, the shares will be held in trust for shareholders for a period of a year. During the lock-up period, EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Verici investment shares.
Verici is a developer of advanced clinical diagnostics for organ transplant. The company is one of three business that have emerged so far from EKF’s preferred partnership agreement to develop healthcare technologies alongside Mount Sinai Health System. The other businesses are Renalytix, which is currently trading on AIM and Nasdaq, and Trellus Health. Both Trellus and Verici are listed on AIM. EKF reported owning around 5.7% of Verici’s shares at the time of the company’s final results announcement in March. The partnership with Mount Sinai is proving fruitful and represents an asset that investors may be overlooking when valuing shares in EKF.
We feel that the company’s core business alone is somewhat undervalued by the current share price. Stripping out net cash of 4.6p per share, the shares trade on a prospective P/E of 14.1 for the current year, falling to 11.4 for fiscal 2023. Add in the projected value of the business investments in the Mount Sinai partnership and the stock looks excessively neglected. Buy."
Covid now in the rear view mirror - new business growth now well underway. Will be good to see some contracts in place for the new fermentation capacity which will start to come on stream later this year. Looks we are also into lots of diagnostic testing opportunities to build on the lab testing capacity we have. Singer happy with update - although have not updated their target price from 62p. Bit of a subdued reaction - looks like this will be slower to recover than we might have thought but every reason to be confident about the future. SB